Pfizer reported better-than-expected Q2 adjusted earnings per share and sales, surpassing analyst consensus estimates. While EPS saw a slight year-over-year decrease, sales increased, indicating resilience in its core business despite challenges.
Pfizer announced its Q2 earnings, revealing adjusted EPS of $0.77 and sales of $15.034 billion, both exceeding analyst expectations. This performance is significant as it demonstrates the company's ability to outperform in a challenging economic environment, despite a slight year-over-year dip in EPS. For traders, this indicates potential short-term positive sentiment for PFE stock, as the company's revenue growth suggests underlying business strength. The key opportunity lies in the market's reaction to these positive surprises, potentially leading to an upward movement in share price, while the risk is that the slight EPS decline could temper enthusiasm.